Sonia Abad

Sonia Abad

Auto-generated profile, based on publicly available information

Sonia Abad

Biomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Unitat de Farmacologia i Farmacognòsia Facultat de Farmàcia, Institut de Biomedicina (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
JFJaume Folch
Jaume Folch
DPDmitry Petrov
Dmitry Petrov
MEMiren Ettcheto
Miren Ettcheto
SASonia Abad
Sonia Abad
Elena Sánchez LópezElena Sánchez López
Elena Sánchez López
Antoni CaminsAntoni Camins
Antoni Camins
Alzheimer’s disease (AD) currently presents one of the biggest healthcare issues in the developed countries. There is no effective treatment capable of slowing down disease progression. In recent years the main focus of research on novel pharmacotherapies was based on the amyloidogenic hypothesis of AD, which posits that the beta amyloid (Aβ) peptide is chiefly responsible for cognitive impairment and neuronal death. The goal of such treatments is (a) to reduce Aβproduction through the inhibition ofβandγsecretase enzymes and (b) to promote dissolution of existing cerebral Aβplaques. However, this approach has proven to be only modestly effective. Recent studies suggest an alternative strategy centred on the inhibition of the downstream Aβsignalling, particularly at the synapse. Aβoligomers may cause aberrant N-methyl-D-aspartate receptor (NMDAR) activation postsynaptically by forming complexes with the cell-surface prion protein (PrPC). PrPC is enriched at the neuronal postsynaptic density, where it interacts with Fyn tyrosine kinase. Fyn activation occurs when Aβis bound to PrPC-Fyn complex. Fyn causes tyrosine phosphorylation of the NR2B subunit of metabotropic glutamate receptor 5 (mGluR5). Fyn kinase blockers masitinib and saracatinib have proven to be efficacious in treating AD symptoms in experimental mouse models of the disease.

4 May 2015 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
JFJaume Folch
Jaume Folch
DPDmitry Petrov
Dmitry Petrov
MEMiren Ettcheto
Miren Ettcheto
IPIgnacio Pedrós
Ignacio Pedrós
SASonia Abad
Sonia Abad
Antoni CaminsAntoni Camins
Antoni Camins
Alzheimer's disease (AD) is a degenerative neurological disorder that is the most common cause of dementia and disability in older patients. Available treatments are symptomatic in nature and are only sufficient to improve the quality of life of AD patients temporarily. A potential strategy, currently under investigation, is to target cell-signaling pathways associated with neurodegeneration, in order to decrease neuroinflammation, excitotoxicity, and to improve cognitive functions. Current review centers on the role of neuroinflammation and the specific contribution of mast cells to AD pathophysiology. The authors look at masitinib therapy and the evidence presented through preclinical and clinical trials. Dual actions of masitinib as an inhibitor of mast cell-glia axis and a Fyn kinase blocker are discussed in the context of AD pathology. Masitinib is in Phase III clinical trials for the treatment of malignant melanoma, mastocytosis, multiple myeloma, gastrointestinal cancer and pancreatic cancer. It is also in Phase II/III clinical trials for the treatment of multiple sclerosis, rheumatoid arthritis and AD. Additional research is warranted to better investigate the potential effects of masitinib in combination with other drugs employed in AD treatment.

3 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJosé Martínez-Clemente
José Martínez-Clemente
RLRaúl López-Arnau
Raúl López-Arnau
SASonia Abad
Sonia Abad
DPDavid Pubill
David Pubill
EEElena Escubedo
Elena Escubedo
JCJorge Camarasa
Jorge Camarasa
Mephedrone is a drug of abuse marketed as ‘bath salts". There are discrepancies concerning its long-term effects. We have investigated the neurotoxicity of mephedrone in mice following different exposition schedules. Schedule 1: four doses of 50 mg/kg. Schedule 2: four doses of 25 mg/kg. Schedule 3: three daily doses of 25 mg/kg, for two consecutive days. All schedules induced, in some animals, an aggressive behavior and hyperthermia as well as a decrease in weight gain. Mephedrone (schedule 1) induced dopaminergic and serotoninergic neurotoxicity that persisted 7 days after exposition. At a lower dose (schedule 2) only a transient dopaminergic injury was found. In the weekend consumption pattern (schedule 3), mephedrone induced dopamine and serotonin transporter loss that was accompanied by a decrease in tyrosine hydroxylase and tryptophan hydroxylase 2 expression one week after exposition. Also, mephedrone induced a depressive-like behavior, as well as a reduction in striatal D2 density, suggesting higher susceptibility to addictive drugs. In cultured cortical neurons, mephedrone induced a concentration-dependent cytotoxic effect. Using repeated doses for 2 days in an elevated ambient temperature we evidenced a loss of frontal cortex dopaminergic and hippocampal serotoninergic neuronal markers that suggest injuries at nerve endings.

1 November 2015 in Life Sciences
Verified
Journal Article
Closed access
JFJaume Folch
Jaume Folch
IPIván Patraca
Iván Patraca
NMNohora Martínez
Nohora Martínez
IPIgnacio Pedrós
Ignacio Pedrós
DPDmitry Petrov
Dmitry Petrov
Antoni CaminsAntoni Camins
Antoni Camins

26 October 2013 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
SASònia Abad
Sònia Abad
AFAlberto Fole
Alberto Fole
NONuria del Olmo
Nuria del Olmo
DPDavid Pubill
David Pubill
Merce PallasMerce Pallas
Merce Pallas
EEElena Escubedo
Elena Escubedo

5 April 2014 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
RLRaúl López-Arnau
Raúl López-Arnau
JMJosé Martínez-Clemente
José Martínez-Clemente
SASonia Abad
Sonia Abad
DPDavid Pubill
David Pubill
JCJordi Camarasa
Jordi Camarasa
EEElena Escubedo
Elena Escubedo
Methylone, a new drug of abuse sold as “bath salts,” has similar effects to ecstasy or cocaine. We have investigated changes in dopaminergic and serotoninergic markers, indicative of neuronal damage induced by methylone in the frontal cortex, hippocampus, and striatum of mice, according to two different treatment schedules. Methylone was given subcutaneously to male Swiss CD1 mice at an ambient temperature of 26 °C. Treatment A consisted of three doses of 25 mg/kg at 3.5-h intervals between doses for two consecutive days, and treatment B consisted of four doses of 25 mg/kg at 3-h intervals in 1 day. Repeated methylone administration induced hyperthermia and a significant loss in body weight. Following treatment A, methylone induced transient dopaminergic (frontal cortex) and serotoninergic (hippocampus) impairment. Following treatment B, transient dopaminergic (frontal cortex) and serotonergic (frontal cortex and hippocampus) changes 7 days after treatment were found. We found evidence of astrogliosis in the CA1 and the dentate gyrus of the hippocampus following treatment B. The animals also showed an increase in immobility time in the forced swim test, pointing to a depressive-like behavior. In cultured cortical neurons, methylone (for 24 and 48 h) did not induce a remarkable cytotoxic effect. The neural effects of methylone differ depending upon the treatment schedule. Neurochemical changes elicited by methylone are apparent when administered at an elevated ambient temperature, four times per day at 3-h intervals, which is in accordance with its short half-life.